Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Rimsza

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase InhibitorsYuan Xiao Zhu, Jasper Ch Wong, Talal Hilal, et al.
Leukemia & Lymphoma|May 27, 2020
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816Chul S Ha, Michael LeBlanc, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.
Blood|September 21, 2007
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphomaKen H Young, Dennis D Weisenburger, Bhavana J Dave, et al.
Biopreservation and Biobanking|August 8, 2025
Advancing HIV and Cancer Research: Implementing an AIDS and Cancer Specimen Resource in Latin AmericaLarissa L S Scholte, Evandro S Mello, Karim Yaqub Ibrahim, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Cancer Cell|April 13, 2016
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaYibin Yang, Priscilla Kelly, Arthur L Shaffer, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
British Journal of Haematology|October 26, 2023
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximabColleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, et al.
Haematologica|November 3, 2009
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypeAna Mozos, Cristina Royo, Elena Hartmann, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase InhibitorsYuan Xiao Zhu, Jasper Ch Wong, Talal Hilal, et al.
Leukemia & Lymphoma|May 27, 2020
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816Chul S Ha, Michael LeBlanc, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.
Blood|September 21, 2007
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphomaKen H Young, Dennis D Weisenburger, Bhavana J Dave, et al.
Biopreservation and Biobanking|August 8, 2025
Advancing HIV and Cancer Research: Implementing an AIDS and Cancer Specimen Resource in Latin AmericaLarissa L S Scholte, Evandro S Mello, Karim Yaqub Ibrahim, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Cancer Cell|April 13, 2016
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaYibin Yang, Priscilla Kelly, Arthur L Shaffer, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
British Journal of Haematology|October 26, 2023
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximabColleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, et al.
Haematologica|November 3, 2009
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypeAna Mozos, Cristina Royo, Elena Hartmann, et al.
Pageof 6